Management should be embarrassed at how their company is just...

Management should be embarrassed at how their company is just the plaything of shorters and day traders. Biotech is turning around from its long-term lows and many analysts are speaking very bullishly about the year ahead with Big Pharma cashed up post Covid and hungry to spend to shore up their pipeline. Meanwhile Clinuvel's new chair issues a letter to explain how critical it is to keep current management because they stopped the share price falling further and are here to keep it steady through choppy waters ahead?!?! You have approval and exclusive rights to sell a potential revolutionary drug but you don't have eternity to execute. Spending years on six patient trials that dose three people then fall off the radar is confusing, almost farcical.
Take a look at Avitas 100 patient trial for Vitiligo. Started two months earlier in mid August. Already recruiting at 16 or so sites and expecting full enrolment by early 2024 with completion mid year. Emulate that Clinuvel.